作者
Matthew D Snape, Chaam L Klinger, Elvis D Daniels, Tessa M John, Helen Layton, Llinos Rollinson, Sarah Pestridge, Sandra Dymond, Eva Galiza, Susan Tansey, Daniel A Scott, Sherryl A Baker, Thomas R Jones, Ly-Mee Yu, William C Gruber, Emilio A Emini, Saul N Faust, Adam Finn, Paul T Heath, Andrew J Pollard
发表日期
2010/12/1
期刊
The Pediatric infectious disease journal
卷号
29
期号
12
页码范围
e80-e90
出版商
LWW
简介
Background: A 2-, 4-, and 12-month schedule of a novel 13-valent-pneumococcal conjugate vaccine (PCV13), containing serotype 1, 3, 4, 5, 6A, 6B 7F, 9V, 14, 18C, 19A, 19F, and 23F polysaccharides individually conjugated to CRM 197 was evaluated in a randomized, double-blind, controlled infant study.
Methods: Two hundred eighty-six healthy infants received PCV13 or the 7-valent-pneumococcal conjugate vaccine (PCV7) at 2, 4, and 12 months of age, alongside a serogroup C meningococcal (MenC) vaccine (2 and 4 months of age), DTaP-IPV-Hib (2, 3, and 4 months), and a Hib-MenC vaccine (12 months). Specific antibody responses were assessed at age 5, 12, and 13 months.
Results: At 13 months of age,> 97% of PCV13 recipients had pneumococcal serotype-specific serum IgG concentrations≥ 0.35 μg/mL for each vaccine serotype except serotype 3 (88.2%), and at least 93% of PCV13 recipients had …
学术搜索中的文章
MD Snape, CL Klinger, ED Daniels, TM John, H Layton… - The Pediatric infectious disease journal, 2010